Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Guangxi Medical University Cancer Hospital | China

Author Profile

Scopus

Orcid id

🌟 Distinguished Scientist Award: Dr. Chen Wang 🌟

Full Name: Chen Wang
Gender: Male
Designation: Associate Research Fellow
Department: Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer
Institution/Organization: Guangxi Medical University Cancer Hospital
Qualification: Ph.D.
Area of Specialization: Oncology Therapeutics and Novel Approaches
Sub Division: Anti-tumor Nanomaterials

πŸ“š Education and Experience

Born in Liaoning, China, in 1988, Dr. Chen Wang has dedicated his career to advancing cancer treatment through innovative research in materials science and engineering. He earned his BS (2010) and MS (2013) degrees from Shenyang University of Technology, followed by a Ph.D. from Harbin Engineering University in 2019. Dr. Wang’s postdoctoral research took place at the Changchun Institute of Applied Chemistry and Southern Medical University. He began his academic career at Jilin University of Chemical Technology and joined Guangxi Medical University Cancer Hospital in 2020, becoming an associate research fellow in 2022.

🧬 Research and Innovations

Dr. Wang specializes in the synthesis and clinical application of novel anti-tumor nanomaterials. His pioneering work on calcium overload as a novel treatment for tumor cells has garnered significant attention. The development of GMCP (GOx@MMPB@CaP-PEG) nanoparticles showcases his innovative approach, combining enhanced intratumor reactive oxygen species (ROS) levels with photothermal therapy to promote apoptosis in tumor cells.

πŸ† Achievements

  • Publications: Nearly 30 SCI-indexed original articles, including 11 as first/corresponding author.
  • Projects: Completed 12 research projects, with 5 as the principal investigator.
  • Patents: Holds 7 patents.
  • Editorial Roles: Serves on the editorial boards and as a reviewer for multiple journals.
  • Memberships: Member of the China Food and Drug Enterprise Quality and Safety Promotion Association.
  • Citations: 495 citations in Scopus/Web of Science.
  • H-index: 13.
  • Impact Factor: Cumulative impact factor of 141.8 over the last three years.

Dr. Wang’s work in oncology therapeutics, particularly in anti-tumor nanomaterials, positions him as a leading figure in his field, making him a deserving recipient of the Distinguished Scientist Award.

🌐 Professional Links

πŸ“„ Certifications

  • Education Proof (Ph.D.): 1021722019110003
  • Government ID (Passport): E36369406

Dr. Chen Wang’s dedication to research, innovation, and the application of novel cancer treatments underscores his significant contributions to the field of oncology therapeutics.

 

πŸ“ŠπŸ”¬Notable Publication:

 

 

 

 

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher AwardΒ 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • ZitateΒ  Β  Β  Β  Β  Β 4439
  • h-indexΒ  Β  Β  Β  35
  • i10-indexΒ  Β  Β 49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION: